STORY HIGHLIGHTS Brii Biosciences acquires BRII-179 assets from VBI Vaccines. The $18 million deal cancels previous agreements and obligations. BRII-179 is in Phase 2 study as a hepatitis B treatment.

CAMBRIDGE, Mass., Jan. 3, 2025 /CNW/ - VBI Vaccines Inc. ("VBI" or the "Company") today announced, that, in connection with its creditor protection proceedings under the Companies' Creditors ...

VBI Vaccines Inc. has completed a restructuring process under the Companies’ Creditors Arrangement Act, resulting in the acquisition by K2 VBI Equity Trust, LLC. All common shares have been ...